Partners & News

Featured Updates

  • NaDeNo Selected for EIC Accelerator Funding

    February 17, 2026

    NaDeNo Selected for EIC Accelerator Funding

    Enabling a phase 1 clinical trial of PACAB-002 and advancement of new product candidates NaDeNo has been selected for the EIC Accelerator, one of Europe’s most competitive innovation funding programs. The blended finance award supports continued advancement of PACAB-002, our intraperitoneal nanoparticle therapy for ovarian cancer, through Phase 1, and positions NaDeNo as a [...]

  • NaDeNo seeks funding ahead of clinical entry

    October 23, 2025

    NaDeNo seeks funding ahead of clinical entry

    Nordic Life Science Days With a base at AstraZeneca’s BioVentureHub, NaDeNo Nanoscience was on home turf when Nordic Life Science Days brought the industry together. “It’s an exciting stage for the company as the technology moves from preclinical to clinical development,” say Annbjørg Eide Falck and Jens Bjørheim from NaDeNo Nanoscience. [...]

NaDeNo Collaborates With Leading Organizations

A selection of partners across the healthcare and research ecosystem

Innovation & Testing

Organizations that contribute to preclinical research, early testing, and technology development.

Clinical Development

Renowned clinical institutions driving patient-focused trials to validate efficacy and safety in real-world settings.

Manufacturing & Supply Chain

Partners enabling production, scalability, and raw material sourcing.

Funding & Ecosystems

Organizations providing financial support, innovation clusters, and strategic networks.

Latest Updates

  • NaDeNo Selected for EIC Accelerator Funding

    February 17, 2026

    NaDeNo Selected for EIC Accelerator Funding

    Enabling a phase 1 clinical trial of PACAB-002 and advancement of new product candidates NaDeNo has been selected for the EIC Accelerator, one of Europe’s most competitive innovation funding programs. The blended finance award supports continued advancement of PACAB-002, our intraperitoneal nanoparticle therapy for ovarian cancer, through Phase 1, and positions NaDeNo as a [...]

  • NaDeNo seeks funding ahead of clinical entry

    October 23, 2025

    NaDeNo seeks funding ahead of clinical entry

    Nordic Life Science Days With a base at AstraZeneca’s BioVentureHub, NaDeNo Nanoscience was on home turf when Nordic Life Science Days brought the industry together. “It’s an exciting stage for the company as the technology moves from preclinical to clinical development,” say Annbjørg Eide Falck and Jens Bjørheim from NaDeNo Nanoscience. [...]

  • NaDeNo Presents at GoCo Investor Day

    September 10, 2025

    NaDeNo Presents at GoCo Investor Day

    Organized by GoCo Health Innovation City and AstraZeneca’s BioVentureHub  See Chief Medical Officer Dr. Jens Bjørheim present and take questions from this event in Gothenburg, Sweden Sept 9th, 2025. https://youtu.be/J4Se-7hpshw?si=wV7qGTkthmrA993U

  • NaDeNo joins AstraZeneca BioVentureHub

    April 3, 2025

    NaDeNo joins AstraZeneca BioVentureHub

    We are proud to announce that NaDeNo Nanoscience AS has been selected to join the AstraZeneca BioVentureHub, located at AstraZeneca’s R&D center in Gothenburg, Sweden. The BioVentureHub is an invitation-only ecosystem designed to foster close collaboration between emerging life science companies and AstraZeneca’s scientific and development teams. As the second Norwegian company to join, NaDeNo’s [...]

  • NaDeNo Welcomes Dr. Jens Bjørheim as Chief Medical Officer

    April 2, 2025

    NaDeNo Welcomes Dr. Jens Bjørheim as Chief Medical Officer

    We’re excited to welcome Jens Bjørheim to the NaDeNo team as our Chief Medical Officer. Jens brings a wealth of experience in clinical development and biotech leadership, and he will play a pivotal role in advancing our lead candidate from preclinical promise to patient impact. As CMO, he will lead our clinical strategy and trial [...]

  • NaDeNo Tops PHOENIX OITB Rankings: A Big Leap Toward Clinical Trials

    February 28, 2025

    NaDeNo Tops PHOENIX OITB Rankings: A Big Leap Toward Clinical Trials

    We’re thrilled to share that out of many exceptional applications, NaDeNo achieved the highest evaluation scores from the prestigious PHOENIX OITB Open Call initiative! This recognition underscores the strength of our proprietary nanoparticle technology and the impact it promises for cancer therapy Thanks to this achievement, we now gain access to PHOENIX OITB comprehensive [...]